0 works0 citations0 h-index

Mitchell Ho

National Institutes of Health(US)National Cancer Institute(US)Center for Cancer Research(US)

Publications by Year

Research Areas

CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Glycosylation and Glycoproteins Research, Toxin Mechanisms and Immunotoxins

Most-Cited Works

→ High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array(2010)946 cited
→ Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors(2006)440 cited
→ Mesothelin targeted cancer immunotherapy(2007)336 cited
→ Glypican-3: A new target for cancer immunotherapy(2010)236 cited
→ Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update(2012)226 cited
→ A Binding Domain on Mesothelin for CA125/MUC16(2008)219 cited

→ Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma(2013)

179 cited

→ Isolation of anti-CD22 Fv with high affinity by Fv display on human cells(2006)178 cited

→ Cancer therapy with antibodies(2024)177 cited

→ Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy(2014)159 cited